proxyvotesnow.com

Home › Companies › Viridian Therapeutics, Inc. › 2025-2026

Viridian Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Viridian Therapeutics, Inc.’s Form 8-K, filed 2026-06-03 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 237Asset managers
  • 1,848Fund votes
  • 2026-06-02Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Viridian Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Viridian Therapeutics, Inc.

These tallies are Viridian Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Viridian Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-02
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Tomas Kiselak 72,363,500---- 14,475,6466,733,104 Majority: yes
Elect Director: Jennifer K. Moses 86,378,842---- 460,3046,733,104 Majority: yes
Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: 92,866,008512,582193,660 ---- Majority: yes
Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers: 83,512,0863,113,724213,336 --6,733,104 Majority: yes

Source: Viridian Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-03 — read the filing on EDGAR.

How asset managers voted at the Viridian Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 237 asset managers that disclosed a Viridian Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Viridian Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 83,512,086AGAINST: 3,113,724

Viridian Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers:”): 83,512,086 for, 3,113,724 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,074,740 outstanding shares: 81% for, 3% against (84% of the company cast a for/against vote).

The 236 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 98%
FOR: 97.7%AGAINST: 2.3%ABSTAIN: 0.0%
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity30,437,5250 00For
BlackRock6,619,19210,929 00For
Vanguard6,448,3013,354 00For
T. Rowe Price5,549,3120 00For
State Street4,582,0712,123 00For
Fairmount Funds Management LLC3,914,4580 00For
Venrock Adviser, LLC3,760,0280 00For
Wellington2,500,1520 00For
GEODE CAPITAL MANAGEMENT, LLC2,338,1510 00For
AllianceBernstein2,014,7390 00For
Novo Holdings A/S2,000,0000 00For
Deep Track Capital, LP1,892,2810 00For
Paradigm Biocapital Advisors LP1,662,3580 00For
Charles Schwab1,466,4850 00For
Federated Hermes1,093,8424,970 00For
Citadel1,060,2780 00For
Fisher Asset Management, LLC697,319250,419 00For
DE Shaw822,5730 00For
RICE HALL JAMES & ASSOCIATES, LLC749,8480 00For
Candriam S.C.A.0711,739 00Against
Victory Capital701,1580 00For
Eversept Partners, LP693,2510 00For
PERCEPTIVE ADVISORS LLC686,6690 00For
MPM BioImpact LLC612,7630 00For
BALYASNY ASSET MANAGEMENT L.P.598,9650 00For

Showing the 25 largest of 236 asset managers. See all 236 in the interactive database.

2. To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 76%1 YEAR 23%

The 231 asset managers below cast 99.9% of the shares they voted on this item FOR (876,931 for, 344 against).

FOR: 876,931 (0.9%)AGAINST: 344 (0.0%)ABSTAIN: 35,217 (0.0%)ONE YEAR: 71,556,871 (76.0%)1 YEAR: 21,206,331 (22.5%)THREE YEARS: 246,978 (0.3%)1-YEAR: 246,078 (0.3%)3 YEARS: 15,612 (0.0%)1.0: 8,328 (0.0%)3.0: 1 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00One Year
BlackRock00 001 Year
Vanguard00 00One Year
T. Rowe Price00 00One Year
State Street00 00One Year
Fairmount Funds Management LLC00 00One Year
Venrock Adviser, LLC00 00One Year
Wellington00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
AllianceBernstein00 00One Year
Novo Holdings A/S00 001 Year
Deep Track Capital, LP00 001 Year
Paradigm Biocapital Advisors LP00 00One Year
Charles Schwab00 001 Year
Federated Hermes00 001 Year
Citadel00 00One Year
Fisher Asset Management, LLC00 00One Year
DE Shaw00 00One Year
RICE HALL JAMES & ASSOCIATES, LLC00 001 Year
Candriam S.C.A.00 00One Year
Victory Capital00 00One Year
PERCEPTIVE ADVISORS LLC686,6690 00For
MPM BioImpact LLC00 001 Year
BALYASNY ASSET MANAGEMENT L.P.00 001 Year
Northern Trust00 001 Year

Showing the 25 largest of 231 asset managers. See all 231 in the interactive database.

3. To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jennifer K. Moses

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 86,378,842WITHHELD: 460,304

Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer K. Moses”): 86,378,842 for, 460,304 withheld, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,074,740 outstanding shares: 84% for, 0.5% withheld (84% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (36,612,700 for, 0 against).

FOR 99.8%
FOR: 36,612,700 (99.9%)ABSTAIN: 38,567 (0.1%)
Largest asset managers voting on “To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until ” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,760,6970 3,3500For
BlackRock3,585,8610 00For
State Street2,984,2810 00For
T. Rowe Price2,198,7810 00For
Charles Schwab728,1760 00For
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford535,6950 00For
Federated Hermes437,4090 00For
Victory Capital349,6350 00For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI170,5970 00For
Dimensional166,4530 00For
Principal160,4130 00For
Brighthouse124,8810 35,2170For
Goldman Sachs152,5840 00For
Bridge Builder Trust148,8380 00For
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual111,4850 00For
CLEARWATER INVESTMENT TRUST100,9770 00For
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Tomas Kiselak

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%
FOR: 72,363,500WITHHELD: 14,475,646

Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Tomas Kiselak”): 72,363,500 for, 14,475,646 withheld, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,074,740 outstanding shares: 70% for, 14% withheld (84% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (30,829,621 for, 0 against).

FOR 84%ABSTAIN 16%
FOR: 30,829,621 (84.1%)ABSTAIN: 5,821,646 (15.9%)
Largest asset managers voting on “To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until ” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,760,6810 3,3660For
BlackRock3,585,8610 00For
State Street8,7990 2,975,4820Abstain
T. Rowe Price2,198,7810 00For
Charles Schwab00 728,1760Abstain
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford00 535,6950Abstain
Federated Hermes00 437,4090Abstain
Victory Capital345,9230 3,7120For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI00 170,5970Abstain
Dimensional00 166,4530Abstain
Principal160,4130 00For
Brighthouse124,8810 35,2170For
Goldman Sachs142,6280 9,9560For
Bridge Builder Trust19,7400 129,0980Abstain
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual00 111,4850Abstain
CLEARWATER INVESTMENT TRUST00 100,9770Abstain
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

5. TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 92,866,008AGAINST: 512,582

Viridian Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”): 92,866,008 for, 512,582 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,074,740 outstanding shares: 90% for, 0.5% against (91% of the company cast a for/against vote).

The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (36,615,931 for, 119 against).

FOR 99.9%
FOR: 36,615,931 (99.9%)AGAINST: 119 (0.0%)ABSTAIN: 35,217 (0.1%)
Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEA” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,764,0461 00For
BlackRock3,585,8610 00For
State Street2,984,163118 00For
T. Rowe Price2,198,7810 00For
Charles Schwab728,1760 00For
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford535,6950 00For
Federated Hermes437,4090 00For
Victory Capital349,6350 00For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI170,5970 00For
Dimensional166,4530 00For
Principal160,4130 00For
Brighthouse124,8810 35,2170For
Goldman Sachs152,5840 00For
Bridge Builder Trust148,8380 00For
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual111,4850 00For
CLEARWATER INVESTMENT TRUST100,9770 00For
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTESCOMPENSATION

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 99.8%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (834 for, 0 against).

FOR: 834 (0.1%)ONE YEAR: 700,377 (99.9%)1 YEAR: 42 (0.0%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP00 00One Year
Eleva Capital SAS00 00One Year
ANTIPODES PARTNERS Ltd8340 00For
Coyle Financial Counsel LLC00 001 Year

Largest Viridian Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Viridian Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 103,074,740 shares outstanding at the time of that meeting.

Top Viridian Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 29.53%
2BlackRock 6.43%
3Vanguard 6.26%
4T. Rowe Price 5.38%
5State Street 4.45%
6Fairmount Funds Management LLC 3.80%
7Venrock Adviser, LLC 3.65%
8Wellington 2.43%
9GEODE CAPITAL MANAGEMENT, LLC 2.27%
10AllianceBernstein 1.95%

Reported Viridian Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Viridian Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Fairmount Funds Management LLC 16.69% 13D
Entities affiliated with Fairmount Funds Management LLC 15.55% DEF14A
Entities affiliated with FMR LLC 7.40% DEF14A
Bellevue Group AG 6.53% 13G
Paradigm BioCapital Advisors LP 6.52% 13G
STATE STREET CORPORATION 5.94% 13G
T. Rowe Price Associates, Inc. 5.58% 13G
Point72 Asset Management, L.P. 5.52% 13G
Deep Track Capital, LP 3.49% 13G
Stephen Mahoney 0.99% DEF14A

Percentages above are of 103,074,740 shares outstanding, as reported by Viridian Therapeutics, Inc. on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viridian Therapeutics, Inc.’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Viridian Therapeutics, Inc.'s shareholder meeting held 2026-06-02, in the 2025-2026 proxy season, 237 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,848 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Viridian Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-03.

Viridian Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).